{"entity":{"id":"richard-baum","kind":"person","name":"Richard P. Baum","aka":[],"tldr":"One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.","summary":"Richard Baum is a specialist in nuclear medicine whom Curanosticum describes as one of the leading experts in therapeutic nuclear medicine and part of its medical team since 2020. The centre offers PET-CT, radioiodine therapy, PSMA radioligand therapy and DOTATOC receptor radionuclide therapy. Before Wiesbaden he built the theranostics programme at the Zentralklinik Bad Berka, where lutetium-177 and yttrium-90 labelled somatostatin analogues were used to treat thousands of patients with neuroendocrine tumours, work that preceded the approvals of lutetium-177 dotatate and lutetium-177 PSMA-617. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"Curanosticum","url":"https://www.curanosticum.de/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide"}],"tags":["leadership"],"related":["lu-177","y-90"],"indications":["neuroendocrine","prostate"],"sections":[],"technologies":["radioligand-therapy","lu177-radioligand-therapy","psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["curanosticum"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Nuclear medicine specialist, Curanosticum Wiesbaden-Frankfurt","institutionId":"curanosticum","specialisms":["Nuclear medicine","Peptide receptor radionuclide therapy","PSMA radioligand therapy","Theranostics"],"profiles":[{"label":"Curanosticum","url":"https://www.curanosticum.de/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide"}],"papers":[{"title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1607427","doi":"10.1056/NEJMoa1607427","note":"Europe PMC author record matched by affiliation"},{"title":"FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2010,"url":"https://doi.org/10.1007/s00259-009-1297-4","doi":"10.1007/s00259-009-1297-4","note":"Europe PMC author record matched by affiliation"},{"title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","journal":"Journal of Nuclear Medicine","year":2017,"url":"https://doi.org/10.2967/jnumed.116.183194","doi":"10.2967/jnumed.116.183194","note":"Europe PMC author record matched by affiliation"}]},"route":"/people/richard-baum/","neighbours":{"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"},{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/"}],"indication":[{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"technology":[{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"institution":[{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/"}],"pairing":[{"id":"ga68-dotatate-then-lutathera","kind":"pairing","name":"68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)","route":"/pairings/ga68-dotatate-then-lutathera/"}],"paper":[{"id":"paper-strosberg-netter1-qol-jco-2018","kind":"paper","name":"Health-related quality of life in the NETTER-1 trial of 177Lu-Dotatate","route":"/key-papers/paper-strosberg-netter1-qol-jco-2018/"},{"id":"paper-baum-prrt-1048-patients-oncotarget-2018","kind":"paper","name":"Results and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms","route":"/key-papers/paper-baum-prrt-1048-patients-oncotarget-2018/"}],"person":[{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","route":"/people/michael-lassmann/"}]}}